Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations

Journal of General Virology

Volumn 95, Issue PART 2, 2014, Pages 363-372

  Bhattacharya, Dipankar ^a   Ansari, Israrul H ^a   Hamatake, Robert ^c   Walker, Jill ^c   Kazmierski, Wieslaw M ^c   Striker, Rob ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; GSK 2336805; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; FLUORESCENCE; GENE DISRUPTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATOCYTES; HUMANS; PROTEIN CONFORMATION; SELECTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84892588133     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.054569-0     Document Type: Article

References (32)

1. Adams, S. R., Campbell, R. E., Gross, L. A., Martin, B. R., Walkup, G. K., Yao, Y., Llopis, J. & Tsien, R. Y. (2002). New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc 124, 6063-6076.
2. Ansari, I. U. & Striker, R. T. (2012). Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus. Viruses 4, 3303-3315.
3. Ansari, I. U., Allen, T., Berical, A., Stock, P. G., Barin, B. & Striker, R. (2013). Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility. Virology 436, 268-273.
4. Bechtel, J., Crosby, R., Wang, A., Woldu, E., Van Horn, S., Horton, J., Remlinger, K., Creech, K., Carballo, L. H. & other authors (2011). In vitro profiling of GSK2336805, a potent and selective inhibitor of HCV NS5A. In EASL 46th Annual Meeting, 31 March-2 April, Berlin, Germany 2011.
5. Bhattacharya, D., Ansari, I. H., Mehle, A. & Striker, R. (2012). Fluorescence resonance energy transfer-based intracellular assay for the conformation of hepatitis C virus drug target NS5A. J Virol 86, 8277-8286.
6. Blight, K. J., McKeating, J. A., Marcotrigiano, J. & Rice, C. M. (2003). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77, 3181-3190.
7. Chen, P., Couch, R., Duan, M., Grimes, R. M., Kazmierski, W. M., Norton, B. A. & Tallant, M. (2010). Preparation of biphenyls end capped with amino acids or peptide derivatives for treating HCV infection. Patent, Publication no. WO 2011028596 A1.
8. Das, S. C., Nayak, D., Zhou, Y. & Pattnaik, A. K. (2006). Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J Virol 80, 6368-6377.
9. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F. & Sato, C. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334, 77-82.
10. Foster, T. L., Belyaeva, T., Stonehouse, N. J., Pearson, A. R. & Harris, M. (2010). All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol 84, 9267-9277.
11. Fridell, R. A., Wang, C., Sun, J. H., O'Boyle, D. R., II, Nower, P., Valera, L., Qiu, D., Roberts, S., Huang, X. & other authors (2011). Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54, 1924-1935.
12. Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J. H. & other authors (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96-100.
13. Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., Seeff, L. B. & American Association for Study of Liver Diseases (2011). An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433-1444.
14. Guedj, J., Dahari, H., Rong, L., Sansone, N. D., Nettles, R. E., Cotler, S. J., Layden, T. J., Uprichard, S. L. & Perelson, A. S. (2013). Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 110, 3991-3996.
15. Hwang, J., Huang, L., Cordek, D. G., Vaughan, R., Reynolds, S. L., Kihara, G., Raney, K. D., Kao, C. C. & Cameron, C. E. (2010). Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 84, 12480-12491.
16. Lee, C., Ma, H., Hang, J. Q., Leveque, V., Sklan, E. H., Elazar, M., Klumpp, K. & Glenn, J. S. (2011). The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414, 10-18.
17. Lemm, J. A., O'Boyle, D., II, Liu, M., Nower, P. T., Colonno, R., Deshpande, M. S., Snyder, L. B., Martin, S. W., St Laurent, D. R. & other authors (2010). Identification of hepatitis C virus NS5A inhibitors. J Virol 84, 482-491.
18. Lohmann, V., Hoffmann, S., Herian, U., Penin, F. & Bartenschlager, R. (2003). Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77, 3007-3019.
19. Lok, A. S., Gardiner, D. F., Lawitz, E., Martorell, C., Everson, G. T., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F. & other authors (2012). Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366, 216-224.
20. Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. (2009). Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83, 4395-4403.
21. Membreno, F. E., Espinales, J. C. & Lawitz, E. J. (2013). Cyclophilin inhibitors for hepatitis C therapy. Clin Liver Dis 17, 129-139.
22. Miyawaki, A. & Tsien, R. Y. (2000). Monitoring protein conformations and interactions by fluorescence resonance energy transfer between mutants of green fluorescent protein. Methods Enzymol 327, 472-500.
23. O'Boyle, I. D. R., Sun, J. H., Nower, P. T., Lemm, J. A., Fridell, R. A., Wang, C., Romine, J. L., Belema, M., Nguyen, V. N. & other authors (2013). Characterizations of HCV NS5A replication complex inhibitors. Virology 444, 343-354.
24. Puyang, X., Poulin, D. L., Mathy, J. E., Anderson, L. J., Ma, S., Fang, Z., Zhu, S., Lin, K., Fujimoto, R. & other authors (2010). Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 54, 1981-1987.
25. Qiu, D., Lemm, J. A., O'Boyle, D. R., II, Sun, J. H., Nower, P. T., Nguyen, V., Hamann, L. G., Snyder, L. B., Deon, D. H. & other authors (2011). The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 92, 2502-2511.
26. Schmitz, U. & Tan, S. L. (2008). NS5A-from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov 3, 77-92.
27. Suk-Fong Lok, A. (2013). HCV NS5A inhibitors in development. Clin Liver Dis 17, 111-121.
28. Targett-Adams, P., Graham, E. J., Middleton, J., Palmer, A., Shaw, S. M., Lavender, H., Brain, P., Tran, T. D., Jones, L. H. & other authors (2011). Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85, 6353-6368.
29. Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. (2005). Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374-379.
30. Tellinghuisen, T. L., Foss, K. L. & Treadaway, J. C. (2008). Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 4, e1000032.
31. van den Hoff, M. J., Moorman, A. F. & Lamers, W. H. (1992). Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res 20, 2902.
32. WHO (2011). Hepatitis C. Fact sheet no. 164. World Health Organization, Geneva, Switzerland.